Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shares fell 3.8% on Wednesday . The stock traded as low as $41.76 and last traded at $41.76, with a volume of 322,528 shares traded. The stock had previously closed at $43.40.

Several research firms have recently weighed in on PCRX. Mizuho reissued an “outperform” rating and issued a $64.00 price objective on shares of Pacira Pharmaceuticals in a research report on Friday, July 1st. Wedbush reissued an “outperform” rating and issued a $113.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, May 4th. Zacks Investment Research downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Piper Jaffray Cos. restated an “overweight” rating and issued a $81.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 3rd. Finally, TheStreet downgraded Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Pacira Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $73.64.

The stock’s market cap is $1.49 billion. The company has a 50-day moving average of $39.48 and a 200-day moving average of $47.78.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.03 by $0.16. During the same period last year, the company posted $0.20 earnings per share. The firm had revenue of $69.60 million for the quarter, compared to the consensus estimate of $67.80 million. The business’s revenue was up 17.8% on a year-over-year basis. Equities analysts forecast that Pacira Pharmaceuticals Inc. will post $0.42 earnings per share for the current year.

In other news, VP Lauren Bullaro Riker sold 938 shares of the company’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $47.66, for a total transaction of $44,705.08. Following the completion of the transaction, the vice president now directly owns 5,945 shares of the company’s stock, valued at $283,338.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Kristen Marie Williams sold 600 shares of the company’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $47.20, for a total transaction of $28,320.00. Following the transaction, the chief accounting officer now directly owns 6,900 shares of the company’s stock, valued at $325,680. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Pacira Pharmaceuticals stock. Stephens Inc. AR boosted its stake in shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,557 shares of the company’s stock after buying an additional 806 shares during the period. Stephens Inc. AR owned approximately 0.06% of Pacira Pharmaceuticals worth $1,655,000 at the end of the most recent reporting period.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.